Krystal Biotech, Inc. (KRYS) Stock Forecast
Data as of Aug 3, 2026Healthcare · Current price $312.37 (-8.27%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 18, 2026 | Geulah Livshits | Chardan Capital | $323.00 | +3.4% |
| Feb 17, 2026 | Roger Song | Jefferies | $371.00 | +18.8% |
| Oct 17, 2025 | Debjit Chattopadhyay | Guggenheim | $224.00 | -28.3% |
| Sep 11, 2024 | Dae Gon Ha | Stifel Nicolaus | $220.00 | -29.6% |
| Sep 2, 2024 | Alec Stranahan | Bank of America Securities | $205.00 | -34.4% |
| Aug 12, 2024 | Gavin Clark-Gartner | Evercore ISI | $206.00 | -34.1% |
| Apr 15, 2024 | Dae Gon Ha | Stifel Nicolaus | $204.00 | -34.7% |
| Nov 7, 2022 | Geulah Livshits | Chardan Capital | $133.00 | -57.4% |
| Aug 8, 2022 | Geulah Livshits | Chardan Capital | $130.00 | -58.4% |
Top Analysts Covering KRYS
KRYS vs Sector & Market
| Metric | KRYS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 14 | 8 | 19 |
| Target Upside | +5.7% | +16316.2% | +17.1% |
| P/E Ratio | 46.11 | 2.97 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $133M | $138M | $143M | 1 |
| 2026-12-31 | $144M | $149M | $155M | 2 |
| 2027-03-31 | $136M | $142M | $147M | 1 |
| 2027-06-30 | $151M | $157M | $163M | 2 |
| 2027-09-30 | $170M | $177M | $183M | 2 |
| 2027-12-31 | $199M | $206M | $214M | 1 |
| 2028-12-31 | $775M | $899M | $1.07B | 4 |
| 2029-12-31 | $988M | $1.15B | $1.36B | 3 |
| 2030-12-31 | $1.25B | $1.45B | $1.72B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $1.92 | $2.02 | $2.12 | 1 |
| 2026-12-31 | $2.12 | $2.23 | $2.34 | 2 |
| 2027-03-31 | $1.91 | $2.01 | $2.10 | 2 |
| 2027-06-30 | $2.18 | $2.29 | $2.40 | 1 |
| 2027-09-30 | $2.60 | $2.73 | $2.86 | 1 |
| 2027-12-31 | $3.24 | $3.40 | $3.56 | 2 |
| 2028-12-31 | $7.66 | $13.46 | $24.91 | 4 |
| 2029-12-31 | $16.64 | $20.30 | $25.27 | 2 |
| 2030-12-31 | $22.23 | $27.11 | $33.75 | 2 |
Frequently Asked Questions
What is the analyst consensus for KRYS?
The consensus among 14 analysts covering Krystal Biotech, Inc. (KRYS) is Buy with an average price target of $336.40.
What is the highest price target for KRYS?
The highest price target for KRYS is $371.00, set by Roger Song at Jefferies on 2026-02-17.
What is the lowest price target for KRYS?
The lowest price target for KRYS is $130.00, set by Geulah Livshits at Chardan Capital on 2022-08-08.
How many analysts cover KRYS?
14 analysts have issued ratings for Krystal Biotech, Inc. in the past 12 months.
Is KRYS a buy or sell right now?
Based on 14 analyst ratings, KRYS has a consensus rating of Buy (2.00/5) with a +5.7% upside to the consensus target of $336.40.
What are the earnings estimates for KRYS?
Analysts estimate KRYS will report EPS of $2.02 for the period ending 2026-09-30, with revenue estimated at $138M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.